Anbio Biotechnology (NASDAQ:NNNN) Shares Down 13.6% – Here’s Why

Anbio Biotechnology (NASDAQ:NNNN)’s stock price fell 13.6% on Friday . The company traded as low as $9.85 and last traded at $8.8650. Approximately 26,117 shares traded hands during mid-day trading, a decline of 41% from the average session volume of 44,500 shares. The stock had previously closed at $10.26.

Wall Street Analyst Weigh In

Separately, Weiss Ratings downgraded shares of Anbio Biotechnology from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, July 29th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has an average rating of “Sell”.

Anbio Biotechnology Trading Down 14.2%

The firm has a 50-day simple moving average of $12.52 and a 200-day simple moving average of $21.22.

Anbio Biotechnology Company Profile

Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products. Our unwavering commitment lies in transforming the diagnostics landscape on a global scale, fostering a paradigm shift towards personalized and decentralized diagnostic solutions. By doing so, we aim to significantly enhance patient prognosis and contribute to the betterment of healthcare worldwide. At Anbio Biotechnology, our extensive portfolio comprises an array of IVD products designed to cater to diverse diagnostic needs.